Literature DB >> 24045280

Role of hepatitis B surface antigen (HBsAg) in identifying true inactive HBsAg carriers infected with genotype C hepatitis B virus.

Sun Young Yim1, Soon Ho Um, Jin Young Jung, Yeon Seok Seo, Hyung Joon Yim, Ho Sang Ryu, Hoon Jai Chun, Yoon Tae Jeen, Chang Duck Kim, Bora Keum, Hong Sik Lee.   

Abstract

BACKGROUND: Inactive and active phases of hepatitis B e antigen-negative chronic hepatitis B virus (HBV) infection are diagnosed by serum HBV DNA levels, with cutoff at 2000 IU/mL. However, it is difficult to distinguish inactive carriers at a single time point because HBV DNA levels can transiently decrease to <2000 IU/mL even in noninactive carriers. GOALS: We aimed to establish the role of serum hepatitis B surface antigen (HBsAg) in identifying "true inactive carriers" among treatment-naive genotype C HBV-infected patients with low viremia. STUDY: A total of 133 hepatitis B e antigen-negative carriers with serum HBV DNA levels of <2000 IU/mL and normal alanine aminotransferase levels were enrolled and followed up for >12 months.
RESULTS: Forty patients (30.1%) were classified as noninactive carriers (HBV DNA ≥2000 IU/mL and/or alanine aminotransferase >40 IU/L) during 12 months from enrollment. No baseline serum HBV DNA levels could identify true inactive carriers with 100% specificity, whereas baseline serum HBsAg levels (50 IU/mL) identified true inactive carriers with 100% specificity and 29% detection rate. Detection rate increased when different cutoff levels were applied to different age groups according to median age (46 y). It was comparable in both younger and older groups (37.2% vs. 38%) even when HBsAg cutoff level was increased in the former (400 vs. 50 IU/mL). Furthermore, none reversed to noninactive phase during long-term follow-up when these cutoff levels were applied.
CONCLUSIONS: Baseline serum HBsAg levels at a single time point can identify persistently true inactive carriers, with different cutoff levels according to age.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24045280     DOI: 10.1097/MCG.0b013e3182a4711d

Source DB:  PubMed          Journal:  J Clin Gastroenterol        ISSN: 0192-0790            Impact factor:   3.062


  5 in total

Review 1.  KASL clinical practice guidelines for management of chronic hepatitis B.

Authors: 
Journal:  Clin Mol Hepatol       Date:  2019-06-12

Review 2.  Virus and Host Testing to Manage Chronic Hepatitis B.

Authors:  Grace Lai-Hung Wong; Vincent Wai-Sun Wong; Henry Lik-Yuen Chan
Journal:  Clin Infect Dis       Date:  2016-06-01       Impact factor: 9.079

3.  Phase Transition Is Infrequent Among North American Adults With e-Antigen-Negative Chronic Hepatitis B and Low-Level Viremia.

Authors:  Kali Zhou; Abdus S Wahed; Stewart Cooper; Adrian M Di Bisceglie; Robert J Fontana; Marc G Ghany; Mandana Khalili; Anna S Lok; Robert Perrillo; William M Lee; Daryl T Y Lau; Richard Sterling; Harry L A Janssen; Norah A Terrault
Journal:  Am J Gastroenterol       Date:  2019-11       Impact factor: 10.864

4.  Role of quantitative hepatitis B surface antigen in predicting inactive carriers and HBsAg seroclearance in HBeAg-negative chronic hepatitis B patients.

Authors:  Teerapat Ungtrakul; Tassanee Sriprayoon; Pattama Kusuman; Pitchayachuda Chunnuan; Kamonwan Soonklang; Gaidganok Sornsamdang; Chirayu U Auewarakul; Tawesak Tanwandee
Journal:  Medicine (Baltimore)       Date:  2017-03       Impact factor: 1.889

5.  Prognosis of Untreated Minimally Active Chronic Hepatitis B Patients in Comparison With Virological Responders by Antivirals.

Authors:  Hye Won Lee; Seung Up Kim; Jun Yong Park; Oidov Baatarkhuu; Do Young Kim; Sang Hoon Ahn; Kwang-Hyub Han; Beom Kyung Kim
Journal:  Clin Transl Gastroenterol       Date:  2019-06       Impact factor: 4.488

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.